{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:35:14Z","timestamp":1769160914989,"version":"3.49.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clim.2024.110182","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T17:33:05Z","timestamp":1709746385000},"page":"110182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus"],"prefix":"10.1016","volume":"262","author":[{"given":"Masayuki","family":"Mizui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihito","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0005","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jaci.2023.09.025","article-title":"Regulatory T cells in dominant immunologic tolerance","volume":"153","author":"Georgiev","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"22","key":"10.1016\/j.clim.2024.110182_bb0010","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10289","key":"10.1016\/j.clim.2024.110182_bb0015","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1172\/JCI78087","article-title":"T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity","volume":"125","author":"Moulton","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 2","key":"10.1016\/j.clim.2024.110182_bb0025","doi-asserted-by":"crossref","first-page":"i78","DOI":"10.1136\/annrheumdis-2011-200641","article-title":"CD3 zeta defects in systemic lupus erythematosus","volume":"71","author":"Takeuchi","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1471-4906(03)00100-5","article-title":"Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE","volume":"24","author":"Tsokos","year":"2003","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0035","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0040","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/art.27452","article-title":"Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice","volume":"62","author":"Deng","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0045","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"18","key":"10.1016\/j.clim.2024.110182_bb0050","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2217\/imt-2020-0215","article-title":"Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia","volume":"12","author":"Newland","year":"2020","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0055","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar3251","article-title":"Abnormalities of T cell signaling in systemic lupus erythematosus","volume":"13","author":"Moulton","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0065","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1073\/pnas.1214207110","article-title":"Splicing factor SF2\/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription","volume":"110","author":"Moulton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0070","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1172\/JCI127949","article-title":"Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity","volume":"129","author":"Katsuyama","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109339","article-title":"Splicing factor SRSF1 is indispensable for regulatory T cell homeostasis and function","volume":"36","author":"Katsuyama","year":"2021","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0080","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.4049\/jimmunol.1300634","article-title":"T cell CD3zeta deficiency enables multiorgan tissue inflammation","volume":"191","author":"Deng","year":"2013","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2024.110182_bb0085","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1084\/jem.20120058","article-title":"Reduced TCR signaling potential impairs negative selection but does not result in autoimmune disease","volume":"209","author":"Hwang","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2024.110182_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.855812","article-title":"Reduction of cell surface T-cell receptor by non-Mitogenic CD3 antibody to mitigate murine lupus","volume":"13","author":"Morita","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0095","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0100","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S2213-8587(22)00384-9","article-title":"Teplizumab approval for type 1 diabetes in the USA","volume":"11","author":"Beran","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"23","key":"10.1016\/j.clim.2024.110182_bb0105","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and beta-cell function in newly diagnosed type 1 diabetes","volume":"789","author":"Ramos","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-065X.1995.tb00092.x","article-title":"Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance","volume":"148","author":"Horak","year":"1995","journal-title":"Immunol. Rev."},{"issue":"5216","key":"10.1016\/j.clim.2024.110182_bb0120","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.7770771","article-title":"Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta","volume":"268","author":"Suzuki","year":"1995","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.clim.2024.110182_bb0135","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clim.2018.11.002","article-title":"Natural and modified IL-2 for the treatment of cancer and autoimmune diseases","volume":"206","author":"Mizui","year":"2019","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/740619","article-title":"The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity","volume":"2010","author":"Lieberman","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0150","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6281","key":"10.1016\/j.clim.2024.110182_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/346271a0","article-title":"Recovery from autoimmunity of MRL\/lpr mice after infection with an interleukin-2\/vaccinia recombinant virus","volume":"346","author":"Gutierrez-Ramos","year":"1990","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0160","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0165","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/943254","article-title":"IL-17 in systemic lupus erythematosus","volume":"2010","author":"Crispin","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0170","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","article-title":"Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation","volume":"26","author":"Laurence","year":"2007","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0175","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","article-title":"IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells","volume":"193","author":"Mizui","year":"2014","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0180","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.it.2012.07.007","article-title":"Application of IL-2 therapy to target T regulatory cell function","volume":"33","author":"Shevach","year":"2012","journal-title":"Trends Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0185","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3389\/fimmu.2018.00786","article-title":"Targeting regulatory T cells to treat patients with systemic lupus erythematosus","volume":"9","author":"Mizui","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2478\/rir-2023-0021","article-title":"Low-dose interleukin-2 therapy in systemic lupus erythematosus","volume":"4","author":"La Cava","year":"2023","journal-title":"Rheumatol Immunol Res"},{"issue":"22","key":"10.1016\/j.clim.2024.110182_bb0195","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.clim.2024.110182_bb0200","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis","volume":"365","author":"Saadoun","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.clim.2024.110182_bb0205","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0210","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-dose IL-2 in the treatment of lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0215","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.clim.2024.110182_bb0220","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0225","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun."},{"key":"10.1016\/j.clim.2024.110182_bb0230","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","article-title":"T cells in systemic lupus erythematosus","volume":"43","author":"Suarez-Fueyo","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0235","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI24895","article-title":"Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus","volume":"115","author":"Katsiari","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0240","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.4049\/jimmunol.1000340","article-title":"Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus","volume":"186","author":"Sunahori","year":"2011","journal-title":"J. Immunol."},{"issue":"30","key":"10.1016\/j.clim.2024.110182_bb0245","doi-asserted-by":"crossref","first-page":"21936","DOI":"10.1074\/jbc.M113.467266","volume":"288","author":"Sunahori","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0250","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/ni.3390","article-title":"Phosphatase PP2A is requisite for the function of regulatory T cells","volume":"17","author":"Apostolidis","year":"2016","journal-title":"Nat. Immunol."},{"issue":"37","key":"10.1016\/j.clim.2024.110182_bb0255","doi-asserted-by":"crossref","first-page":"32366","DOI":"10.1074\/jbc.M111.245811","article-title":"A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus","volume":"286","author":"Rauen","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.clim.2024.110182_bb0260","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1172\/JCI22854","article-title":"Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV","volume":"115","author":"Juang","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.30085","article-title":"Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium\/calmodulin-dependent protein kinase type IV","volume":"63","author":"Ichinose","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0270","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI73411","article-title":"CaMK4-dependent activation of AKT\/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance","volume":"124","author":"Koga","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0275","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.4049\/jimmunol.1501603","article-title":"Cutting edge: Nanogel-based delivery of an inhibitor of CaMK4 to CD4+ T cells suppresses experimental autoimmune encephalomyelitis and lupus-like disease in mice","volume":"195","author":"Otomo","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0280","doi-asserted-by":"crossref","first-page":"12993","DOI":"10.1038\/ncomms12993","article-title":"ICER is requisite for Th17 differentiation","volume":"7","author":"Yoshida","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0285","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41423-022-00874-1","article-title":"The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription","volume":"19","author":"Hisada","year":"2022","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0290","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41467-024-45080-x","article-title":"CaMK4 controls follicular helper T cell expansion and function during normal and autoimmune T-dependent B cell responses","volume":"15","author":"Scherlinger","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2024.110182_bb0295","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2019.01299","article-title":"Ikaros zinc finger transcription factors: regulators of cytokine signaling pathways and CD4(+) T helper cell differentiation","volume":"10","author":"Powell","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0300","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/ng.472","article-title":"Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus","volume":"41","author":"Han","year":"2009","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.clim.2024.110182_bb0305","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajhg.2012.02.023","article-title":"Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study","volume":"90","author":"Lessard","year":"2012","journal-title":"Am. J. Hum. Genet."},{"issue":"21","key":"10.1016\/j.clim.2024.110182_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218383","article-title":"Trans-ancestral fine-mapping and epigenetic annotation as tools to delineate functionally relevant risk alleles at IKZF1 and IKZF3 in systemic lupus erythematosus","volume":"21","author":"Vyse","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0315","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.4049\/jimmunol.1601725","article-title":"Aiolos overexpression in systemic lupus erythematosus B cell subtypes and BAFF-induced memory B cell differentiation are reduced by CC-220 modulation of Cereblon activity","volume":"199","author":"Nakayama","year":"2017","journal-title":"J. Immunol."},{"issue":"6168","key":"10.1016\/j.clim.2024.110182_bb0320","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"issue":"5971","key":"10.1016\/j.clim.2024.110182_bb0325","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0330","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of Iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0335","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.clim.2024.110182_bb0340","doi-asserted-by":"crossref","first-page":"13751","DOI":"10.1074\/jbc.M114.558197","article-title":"Transcription factor Ikaros represses protein phosphatase 2A (PP2A) expression through an intronic binding site","volume":"289","author":"Nagpal","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.clim.2024.110182_bb0345","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41584-022-00815-2","article-title":"Ikaros, Aiolos and other moving targets to treat SLE","volume":"18","author":"Boulougoura","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0350","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/art.42112","article-title":"Role of Glutaminase 2 in promoting CD4+ T cell production of Interleukin-2 by supporting antioxidant defense in systemic lupus erythematosus","volume":"74","author":"Hisada","year":"2022","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0355","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2024.110182_bb0360","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.4049\/jimmunol.0903595","article-title":"Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL\/6-lpr\/lpr mice","volume":"184","author":"Kyttaris","year":"2010","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0365","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4049\/jimmunol.1700418","article-title":"IL-23 limits the production of IL-2 and promotes autoimmunity in lupus","volume":"199","author":"Dai","year":"2017","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12\/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J. Dermatolog. Treat."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0375","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"Alimentiv translational research C: IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10155","key":"10.1016\/j.clim.2024.110182_bb0380","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0385","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0390","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/cimb45050275","article-title":"Is Th17-targeted therapy effective in systemic lupus erythematosus?","volume":"45","author":"Petric","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0395","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41467-020-16636-4","article-title":"Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0400","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.immuni.2012.08.014","article-title":"Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis","volume":"37","author":"Pisitkun","year":"2012","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0405","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1400931","article-title":"IL-17 promotes murine lupus","volume":"193","author":"Amarilyo","year":"2014","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0410","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.38955","article-title":"Function of the Th17\/interleukin-17A immune response in murine lupus nephritis","volume":"67","author":"Schmidt","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0415","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/BOR.0000000000000685","article-title":"Metabolic control of T cells in autoimmunity","volume":"32","author":"Kono","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/25785826.2022.2140503","article-title":"New insights into the metabolism of Th17 cells","volume":"46","author":"Kono","year":"2023","journal-title":"Immunol Med"},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0425","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cmet.2014.05.004","article-title":"The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function","volume":"20","author":"Macintyre","year":"2014","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.clim.2024.110182_bb0430","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110182_bb0435","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3389\/fimmu.2019.00833","article-title":"Targeting T cell activation and lupus autoimmune phenotypes by inhibiting glucose transporters","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0440","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.20110278","article-title":"HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.clim.2024.110182_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002202","article-title":"Lactate regulates metabolic and pro-inflammatory circuits in control of T cell migration and effector functions","volume":"13","author":"Haas","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.clim.2024.110182_bb0450","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7(274):274ra218","author":"Yin","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0455","article-title":"Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI","volume":"4","author":"Kono","year":"2019","journal-title":"Insight"},{"issue":"10","key":"10.1016\/j.clim.2024.110182_bb0460","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190613","article-title":"PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation","volume":"217","author":"Damasceno","year":"2020","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0465","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.40785","article-title":"Promotion of calcium\/calmodulin-dependent protein kinase 4 by GLUT1-dependent glycolysis in systemic lupus erythematosus","volume":"71","author":"Koga","year":"2019","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.clim.2024.110182_bb0470","article-title":"Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity","volume":"8(48):eadc9657","author":"Scherlinger","year":"2022","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0475","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0092-8674(92)90178-F","article-title":"More is better: activators and repressors from the same gene","volume":"68","author":"Foulkes","year":"1992","journal-title":"Cell"},{"issue":"37","key":"10.1016\/j.clim.2024.110182_bb0480","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1073\/pnas.1805717115","article-title":"Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation","volume":"115","author":"Kono","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10126","key":"10.1016\/j.clim.2024.110182_bb0485","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clim.2024.110182_bb0490","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.22085","article-title":"Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus","volume":"54","author":"Fernandez","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0495","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1177\/0961203319877239","article-title":"Restoring T-helper 17 cell\/regulatory T-cell balance and decreasing disease activity by rapamycin and all-trans retinoic acid in patients with systemic lupus erythematosus","volume":"28","author":"Chu","year":"2019","journal-title":"Lupus"},{"issue":"24","key":"10.1016\/j.clim.2024.110182_bb0500","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00018-015-1976-1","article-title":"Rapamycin inhibits BAFF-stimulated cell proliferation and survival by suppressing mTOR-mediated PP2A-Erk1\/2 signaling pathway in normal and neoplastic B-lymphoid cells","volume":"72","author":"Zeng","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.clim.2024.110182_bb0505","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1172\/JCI30398","article-title":"Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus","volume":"117","author":"Wu","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0510","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","article-title":"Control of T(H)17\/T(reg) balance by hypoxia-inducible factor 1","volume":"146","author":"Dang","year":"2011","journal-title":"Cell"},{"issue":"538","key":"10.1016\/j.clim.2024.110182_bb0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1620","article-title":"Kidney tissue hypoxia dictates T cell-mediated injury in murine lupus nephritis","volume":"12","author":"Chen","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0520","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/art.41019","article-title":"Glutaminase 1 inhibition reduces glycolysis and ameliorates lupus-like disease in MRL\/lpr mice and experimental autoimmune encephalomyelitis","volume":"71","author":"Kono","year":"2019","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.clim.2024.110182_bb0525","first-page":"1869","article-title":"inhibition reduces glycolysis and ameliorates lupus-like disease in MRL\/lpr mice and experimental autoimmune encephalomyelitis. Arthritis","volume":"71","author":"Kono","year":"2019","journal-title":"Rheumatol"},{"issue":"7666","key":"10.1016\/j.clim.2024.110182_bb0530","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nature23475","article-title":"Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism","volume":"548","author":"Xu","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clim.2024.110182_bb0535","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41467-023-36594-x","article-title":"Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming","volume":"14","author":"Aso","year":"2023","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0540","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/art.42284","article-title":"Modulation of the Itaconate pathway attenuates murine lupus","volume":"74","author":"Blanco","year":"2022","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.clim.2024.110182_bb0545","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/art.10968","article-title":"Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine","volume":"48","author":"Bednarski","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.clim.2024.110182_bb0550","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1177\/0961203320928412","article-title":"Rituximab use as induction therapy for lupus nephritis: a systematic review","volume":"29","author":"Stolyar","year":"2020","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.clim.2024.110182_bb0555","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102980","article-title":"Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis","volume":"20","author":"Jamaly","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.clim.2024.110182_bb0565","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/0961203317717083","article-title":"Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men","volume":"27","author":"Schwarting","year":"2018","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.clim.2024.110182_bb0570","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/rheumatology\/keac528","article-title":"SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis","volume":"62","author":"Itotagawa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.clim.2024.110182_bb0575","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of Belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624000731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624000731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T06:57:00Z","timestamp":1720594620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624000731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":115,"alternative-id":["S1521661624000731"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110182","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110182"}}